Aberrant Activation of Five Embryonic Stem Cell-specific Genes Robustly Predicts a High Risk of Relapse in Breast Cancers

Overview

Journal BMC Genomics

Publisher Biomed Central

Specialty Genetics

Date 2023 Aug 17

PMID 37592220

Authors

Emmanuelle Jacquet

Florent Chuffart

Anne-Laure Vitte

Eleni Nika

Mireille Mousseau

Saadi Khochbin

Sophie Rousseaux

Ekaterina Bourova-Flin

Affiliations

Soon will be listed here.

Abstract

Background: In breast cancer, as in all cancers, genetic and epigenetic deregulations can result in out-of-context expressions of a set of normally silent tissue-specific genes. The activation of some of these genes in various cancers empowers tumours cells with new properties and drives enhanced proliferation and metastatic activity, leading to a poor survival prognosis.

Results: In this work, we undertook an unprecedented systematic and unbiased analysis of out-of-context activations of a specific set of tissue-specific genes from testis, placenta and embryonic stem cells, not expressed in normal breast tissue as a source of novel prognostic biomarkers. To this end, we combined a strict machine learning framework of transcriptomic data analysis, and successfully created a new robust tool, validated in several independent datasets, which is able to identify patients with a high risk of relapse. This unbiased approach allowed us to identify a panel of five biomarkers, DNMT3B, EXO1, MCM10, CENPF and CENPE, that are robustly and significantly associated with disease-free survival prognosis in breast cancer. Based on these findings, we created a new Gene Expression Classifier (GEC) that stratifies patients. Additionally, thanks to the identified GEC, we were able to paint the specific molecular portraits of the particularly aggressive tumours, which show characteristics of male germ cells, with a particular metabolic gene signature, associated with an enrichment in pro-metastatic and pro-proliferation gene expression.

Conclusions: The GEC classifier is able to reliably identify patients with a high risk of relapse at early stages of the disease. We especially recommend to use the GEC tool for patients with the luminal-A molecular subtype of breast cancer, generally considered of a favourable disease-free survival prognosis, to detect the fraction of patients undergoing a high risk of relapse.

Citing Articles

Identification of immunogenic HLA-A*02:01 epitopes associated with HCC for immunotherapy development.

Maino A, Bourov A-Flin E, Decaens T, Khochbin S, Macek Jilkova Z, Rousseaux S Hepatol Commun. 2025; 9(3).

PMID: 40008881 PMC: 11868434. DOI: 10.1097/HC9.0000000000000659.

A comparative analysis of gene expression profiling by statistical and machine learning approaches.

Bontonou M, Haget A, Boulougouri M, Audit B, Borgnat P, Arbona J Bioinform Adv. 2025; 5(1):vbae199.

PMID: 39897946 PMC: 11783302. DOI: 10.1093/bioadv/vbae199.

References

Gao M, Wang J, Rousseaux S, Tan M, Pan L, Peng L . Metabolically controlled histone H4K5 acylation/acetylation ratio drives BRD4 genomic distribution. Cell Rep. 2021; 36(4):109460. DOI: 10.1016/j.celrep.2021.109460. View

Zhang S, Xie Y, Tian T, Yang Q, Zhou Y, Qiu J . High expression levels of centromere protein A plus upregulation of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin signaling pathway affect chemotherapy response and prognosis in patients with breast cancer. Oncol Lett. 2021; 21(5):410. PMC: 8020387. DOI: 10.3892/ol.2021.12671. View

Morozumi Y, Boussouar F, Tan M, Chaikuad A, Jamshidikia M, Colak G . Atad2 is a generalist facilitator of chromatin dynamics in embryonic stem cells. J Mol Cell Biol. 2015; 8(4):349-62. PMC: 4991664. DOI: 10.1093/jmcb/mjv060. View

Chen H, Wu F, Xu H, Wei G, Ding M, Xu F . Centromere protein F promotes progression of hepatocellular carcinoma through ERK and cell cycle-associated pathways. Cancer Gene Ther. 2021; 29(7):1033-1042. DOI: 10.1038/s41417-021-00404-7. View

Wang J, Mi J, Debernardi A, Vitte A, Emadali A, Meyer J . A six gene expression signature defines aggressive subtypes and predicts outcome in childhood and adult acute lymphoblastic leukemia. Oncotarget. 2015; 6(18):16527-42. PMC: 4599287. DOI: 10.18632/oncotarget.4113. View

Rousseaux S, Wang J, Khochbin S . Cancer hallmarks sustained by ectopic activations of placenta/male germline genes. Cell Cycle. 2013; 12(15):2331-2. PMC: 3841303. DOI: 10.4161/cc.25545. View

Wang S, Cai W, Li J, An W, Zheng H, Liao M . Bioinformatics Analysis and Experimental Study of Exonuclease 1 Gene in Lung Adenocarcinoma. Biochem Genet. 2022; 60(6):1934-1945. DOI: 10.1007/s10528-022-10190-y. View

Ibrahim M, Klement J, Lu C, Redd P, Xiao W, Yang D . Myeloid-Derived Suppressor Cells Produce IL-10 to Elicit DNMT3b-Dependent IRF8 Silencing to Promote Colitis-Associated Colon Tumorigenesis. Cell Rep. 2018; 25(11):3036-3046.e6. PMC: 6319669. DOI: 10.1016/j.celrep.2018.11.050. View

Schwartz B, Hofer M, Lemieux M, Bauer D, Cameron M, West N . Differentiation of NUT midline carcinoma by epigenomic reprogramming. Cancer Res. 2011; 71(7):2686-96. PMC: 3070805. DOI: 10.1158/0008-5472.CAN-10-3513. View

10.

Simpson A, Caballero O, Jungbluth A, Chen Y, Old L . Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer. 2005; 5(8):615-25. DOI: 10.1038/nrc1669. View

11.

Micevic G, Muthusamy V, Damsky W, Theodosakis N, Liu X, Meeth K . DNMT3b Modulates Melanoma Growth by Controlling Levels of mTORC2 Component RICTOR. Cell Rep. 2016; 14(9):2180-2192. PMC: 4785087. DOI: 10.1016/j.celrep.2016.02.010. View

12.

So J, Yang H, Park W, Skrypek N, Ishii H, Chen J . DNA Methyltransferase 3B-Mediated Intratumoral Heterogeneity and Therapeutic Targeting in Breast Cancer Recurrence and Metastasis. Mol Cancer Res. 2022; 20(11):1674-1685. PMC: 9633364. DOI: 10.1158/1541-7786.MCR-21-0887. View

13.

Naderi A, Teschendorff A, Barbosa-Morais N, Pinder S, Green A, Powe D . A gene-expression signature to predict survival in breast cancer across independent data sets. Oncogene. 2006; 26(10):1507-16. DOI: 10.1038/sj.onc.1209920. View

14.

Li H, Chen Y, Feng W, Cai H, Mei Y, Jiang Y . Loss of the Opa interacting protein 5 inhibits breast cancer proliferation through miR-139-5p/NOTCH1 pathway. Gene. 2016; 603:1-8. DOI: 10.1016/j.gene.2016.11.046. View

15.

Reynoird N, Schwartz B, Delvecchio M, Sadoul K, Meyers D, Mukherjee C . Oncogenesis by sequestration of CBP/p300 in transcriptionally inactive hyperacetylated chromatin domains. EMBO J. 2010; 29(17):2943-52. PMC: 2944051. DOI: 10.1038/emboj.2010.176. View

16.

Rhee I, Bachman K, Park B, Jair K, Yen R, Schuebel K . DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature. 2002; 416(6880):552-6. DOI: 10.1038/416552a. View

17.

Li S, Shi X, Li J, Zhou X . Pathogenicity of the MAGE family. Oncol Lett. 2021; 22(6):844. PMC: 8561213. DOI: 10.3892/ol.2021.13105. View

18.

Irizarry R, Hobbs B, Collin F, Beazer-Barclay Y, Antonellis K, Scherf U . Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics. 2003; 4(2):249-64. DOI: 10.1093/biostatistics/4.2.249. View

19.

Rousseaux S, Debernardi A, Jacquiau B, Vitte A, Vesin A, Nagy-Mignotte H . Ectopic activation of germline and placental genes identifies aggressive metastasis-prone lung cancers. Sci Transl Med. 2013; 5(186):186ra66. PMC: 4818008. DOI: 10.1126/scitranslmed.3005723. View

20.

McFarlane R, Feichtinger J, Larcombe L . Germline/meiotic genes in cancer: new dimensions. Cell Cycle. 2015; 14(6):791-2. PMC: 4614398. DOI: 10.1080/15384101.2015.1010965. View